These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 19167257)
1. Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells. Rigat B; Mahuran D Mol Genet Metab; 2009 Apr; 96(4):225-32. PubMed ID: 19167257 [TBL] [Abstract][Full Text] [Related]
2. In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse models. Sun Y; Liou B; Quinn B; Ran H; Xu YH; Grabowski GA PLoS One; 2009 Oct; 4(10):e7320. PubMed ID: 19809509 [TBL] [Abstract][Full Text] [Related]
3. Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. Yu Z; Sawkar AR; Whalen LJ; Wong CH; Kelly JW J Med Chem; 2007 Jan; 50(1):94-100. PubMed ID: 17201413 [TBL] [Abstract][Full Text] [Related]
4. Endoplasmic reticulum Ca2+ increases enhance mutant glucocerebrosidase proteostasis. Ong DS; Mu TW; Palmer AE; Kelly JW Nat Chem Biol; 2010 Jun; 6(6):424-32. PubMed ID: 20453863 [TBL] [Abstract][Full Text] [Related]
6. Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease. Yu L; Ikeda K; Kato A; Adachi I; Godin G; Compain P; Martin O; Asano N Bioorg Med Chem; 2006 Dec; 14(23):7736-44. PubMed ID: 16919960 [TBL] [Abstract][Full Text] [Related]
7. Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Sawkar AR; Cheng WC; Beutler E; Wong CH; Balch WE; Kelly JW Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15428-33. PubMed ID: 12434014 [TBL] [Abstract][Full Text] [Related]
8. The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Steet RA; Chung S; Wustman B; Powe A; Do H; Kornfeld SA Proc Natl Acad Sci U S A; 2006 Sep; 103(37):13813-8. PubMed ID: 16945909 [TBL] [Abstract][Full Text] [Related]
9. Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry. Tropak MB; Kornhaber GJ; Rigat BA; Maegawa GH; Buttner JD; Blanchard JE; Murphy C; Tuske SJ; Coales SJ; Hamuro Y; Brown ED; Mahuran DJ Chembiochem; 2008 Nov; 9(16):2650-62. PubMed ID: 18972510 [TBL] [Abstract][Full Text] [Related]
10. The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase. Khanna R; Benjamin ER; Pellegrino L; Schilling A; Rigat BA; Soska R; Nafar H; Ranes BE; Feng J; Lun Y; Powe AC; Palling DJ; Wustman BA; Schiffmann R; Mahuran DJ; Lockhart DJ; Valenzano KJ FEBS J; 2010 Apr; 277(7):1618-38. PubMed ID: 20148966 [TBL] [Abstract][Full Text] [Related]
11. Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants. Sawkar AR; Schmitz M; Zimmer KP; Reczek D; Edmunds T; Balch WE; Kelly JW ACS Chem Biol; 2006 May; 1(4):235-51. PubMed ID: 17163678 [TBL] [Abstract][Full Text] [Related]
13. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Lieberman RL; Wustman BA; Huertas P; Powe AC; Pine CW; Khanna R; Schlossmacher MG; Ringe D; Petsko GA Nat Chem Biol; 2007 Feb; 3(2):101-7. PubMed ID: 17187079 [TBL] [Abstract][Full Text] [Related]
14. Rapid assembly of a library of lipophilic iminosugars via the thiol-ene reaction yields promising pharmacological chaperones for the treatment of Gaucher disease. Goddard-Borger ED; Tropak MB; Yonekawa S; Tysoe C; Mahuran DJ; Withers SG J Med Chem; 2012 Mar; 55(6):2737-45. PubMed ID: 22360565 [TBL] [Abstract][Full Text] [Related]
15. pH-Responsive Trihydroxylated Piperidines Rescue The Glucocerebrosidase Activity in Human Fibroblasts Bearing The Neuronopathic Gaucher-Related L444P/L444P Mutations in GBA1 Gene. Davighi MG; Matassini C; Clemente F; Paoli P; Morrone A; Cacciarini M; Goti A; Cardona F Chembiochem; 2024 Jan; 25(1):e202300730. PubMed ID: 37877519 [TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. Maegawa GH; Tropak MB; Buttner JD; Rigat BA; Fuller M; Pandit D; Tang L; Kornhaber GJ; Hamuro Y; Clarke JT; Mahuran DJ J Biol Chem; 2009 Aug; 284(35):23502-16. PubMed ID: 19578116 [TBL] [Abstract][Full Text] [Related]
17. New insights into the pharmacological chaperone activity of c2-substituted glucoimidazoles for the treatment of Gaucher disease. Li Z; Li T; Dai S; Xie X; Ma X; Zhao W; Zhang W; Li J; Wang PG Chembiochem; 2013 Jul; 14(10):1239-47. PubMed ID: 23775891 [TBL] [Abstract][Full Text] [Related]
18. A comparative computational approach toward pharmacological chaperones (NN-DNJ and ambroxol) on N370S and L444P mutations causing Gaucher's disease. Thirumal Kumar D; Iyer S; Christy JP; Siva R; Tayubi IA; George Priya Doss C; Zayed H Adv Protein Chem Struct Biol; 2019; 114():315-339. PubMed ID: 30635084 [TBL] [Abstract][Full Text] [Related]